Intranasal insulin stabilized or improved cognition and function and preserved cerebral metabolic rate of glucose in brain regions affected by Alzheimer’s disease, concluded researchers from a phase II trial. But more and larger trials are needed before any conclusions can be drawn, they also cautioned.
Insulin is important to normal brain function, and reduced insulin levels may contribute to Alzheimer’s disease, researchers noted. To examine the effects of intranasal insulin in adults with amnestic mild cognitive impairment or Alzheimer’s disease, researchers conducted a randomized, double-blind, placebo-controlled trial in a VA medical center.
The intent-to-treat sample consisted of 104 adults with amnestic mild cognitive impairment (n=64) or mild to moderate Alzheimer’s disease (n=40) defined as Clinical Dementia Rating scores of 0.5-1 and Mini-Mental State Examination scores greater than 15.
Participants received Read more »
*This blog post was originally published at ACP Internist*